Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Companys Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in…
